Topotecan (hydrochloride)
Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a Topoisomerase I inhibitor with potent antineoplastic activities.
Product Specifications
CAS Number
[119413-54-6]
Product Name Alternative
SKF 104864A (hydrochloride) ; NSC 609669 (hydrochloride)
UNSPSC
12352005
Hazard Statement
H301, H340
Target
Apoptosis; Autophagy; Topoisomerase
Type
Natural Products
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Topotecan-Hydrochloride.html
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 33.33 mg/mL (ultrasonic)
Smiles
[H]Cl.O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(CN(C)C)C(O)=CC=C5N=C4C3=C2)=O
Molecular Formula
C23H24ClN3O5
Molecular Weight
457.91
Precautions
H301, H340
References & Citations
[1]Zhang FL, et al. PLoS One. 2013 Nov 26;8 (11) :e81815.Topoisomerase I inhibitors, Shikonin and Topotecan, inhibit growth and induce apoptosis of glioma cells andglioma stem cells.|[2]Kumar S, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011 Sep 1;17 (17) :5656-67.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Natural Products
Clinical Information
Launched
Isoform
Topo I
Citation 01
Biochem Pharmacol. 2023 Oct:216:115769.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|bioRxiv. 2024 Jul 7:2024.07.04.601620.|bioRxiv. 2025 Sep 21.|Cancer Res. 2023 Dec 15;83 (24) :4015-4029.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2025 Jan 11;44 (1) :115171.|Cell Rep. 2025 Mar 25;44 (4) :115466.|Eur J Med Chem. 2024 Dec 5:279:116842.|FASEB Bioadv. 2020 Mar 7;2 (4) :254-263.|Indiana University Indianapolis. 2025.|Int J Mol Sci. 2025 Apr 17;26 (8) :3790.|J Extracell Vesicles. 2022 Apr;11 (4) :e12206.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Nat Prod. 2025 Mar 28;88 (3) :688-705.|J Transl Med. 2024 Aug 14;22 (1) :766.|J Virol. 2019 May 15;93 (11) :e02230-18.|Nat Commun. 2025 Jun 2;16 (1) :5126.|NPJ Precis Oncol. 2024 Jun 5;8 (1) :128.|Pharmacol Res. 2024 May 9:204:107208.|Universitat Autònoma de Barcelona. Biologia Molecular i Biomedicina. 2022 Aug.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|bioRxiv. 2023 Apr 14.|Cancer Immunol Res. 2023 May 3;11 (5) :583-599.|Cancers (Basel) . 2021 Dec 31;14 (1) :193.|Cell Commun Signal. 2024 Jun 13;22 (1) :325.|Cell Death Dis. 2024 Jan 18;15 (1) :66.|J Biomed Inform. 2023 Jun:142:104383.|J Exp Clin Cancer Res. 2018 Dec 20;37 (1) :321. |J Immunol. 2022 Jul 1;209 (1) :171-179.|Nat Commun. 2019 Aug 21;10 (1) :3761.|Pharmaceutics. 2022 Nov 24;14 (12) :2595.|Phytochemistry. 2021 Nov:191:112910.|Sci Rep. 2019 Oct 22;9 (1) :15099.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
124804-ML405 100 µL
CDKL5 (STK9, Cyclin-dependent Kinase-like 5, Serine/Threonine-protein Kinase 9) (MaxLight 405) discontinued
Ask
View Details 
134227-FITC 100 µL
TAS2R20 (Taste Receptor Type 2 Member 20, T2R20, Taste Receptor Type 2 Member 49, TAS2R49, T2R49, Taste Receptor Type 2 Member 56, T2R56) (FITC)
Ask
View Details